Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. reports developments in physician enablement technology and Medicare Advantage insurance. The company offers PPO and HMO Medicare Advantage plans and uses its Clover Assistant software platform to aggregate patient data, support clinical decision-making, and address chronic disease management for Medicare populations.
Recurring Clover Health news includes quarterly and annual results, Medicare Advantage membership trends, medical cost and profitability metrics, and guidance updates. Company updates also cover Counterpart Health, the subsidiary that extends the data-driven physician enablement platform beyond Clover’s Medicare Advantage plan, including interoperability collaborations, patient data access, and clinical research tied to conditions such as diabetes, chronic kidney disease, congestive heart failure, COPD, and preventive care.
Clover Health (Nasdaq: CLOV) announced that Interim Chief Financial Officer Clay Thornton will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 8:30 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A will be available on Clover Health’s investor relations website.
Clover Health describes itself as a physician enablement technology company focused on Medicare, offering PPO and HMO Medicare Advantage plans and extending its Clover Assistant platform via its subsidiary Counterpart Health.
Clover Health (Nasdaq:CLOV) will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a webcast at 5:00 p.m. Eastern Time to discuss quarterly business and financial performance, with a live and archived stream available.
Clover Health (Nasdaq:CLOV) subsidiary Counterpart Health released a whitepaper analyzing Counterpart Assistant (CA) use in high-risk care transitions for its Medicare Advantage population.
CA-enabled PCPs were associated with better HEDIS® Transitions of Care and FMC performance, including 33% higher discharge information receipt, 11% higher medication reconciliation, and 9% higher ED follow-up rates.
Clover Health (Nasdaq: CLOV) reported Q1 2026 results, delivering GAAP Net Income of $27.3M and total revenues of $749.2M. Medicare Advantage membership reached 155,773 (up 51% YoY). Consolidated Gross Profit was $159.5M and Adjusted EBITDA was $40.3M. The company provided 2026 guidance: revenues $2.81B–$2.92B, Consolidated Gross Profit $470M–$510M, Adjusted EBITDA $50M–$70M, and GAAP Net Income $0M–$20M.
Clover Health (Nasdaq: CLOV) will release its First Quarter 2026 financial results after market close on Wednesday, May 6, 2026. Management will host a webcast presentation at 5:00 p.m. Eastern Time that day to discuss business and quarterly financial performance.
The live webcast requires registration at the provided URL and will be archived on Clover Health's Investor Relations website and remain accessible for 12 months.
Clover Health (Nasdaq: CLOV) announced a live partnership with HealthEx on April 7, 2026 that lets Medicare Advantage members securely access and share clinical records and claims data via Counterpart Health infrastructure.
Members can verify identity, authorize consent, and connect data to digital tools and providers, creating a more complete, portable health record governed by each recipient's privacy terms.
Clover Health (Nasdaq: CLOV) announced that Peter Kuipers stepped down as Chief Financial Officer effective March 30, 2026, remaining as an advisor through April 24, 2026. The board named Clay Thornton, divisional CFO of the company's insurance plan, as Interim CFO effective immediately. The company reiterated its most recently issued full fiscal year 2026 financial guidance, previously updated on February 26, 2026.
This leadership change emphasizes continuity by promoting an internal finance leader with Medicare Advantage experience while the company maintains its prior guidance.
Counterpart Health (Nasdaq: CLOV) released a whitepaper showing use of Counterpart Assistant (CA) clinical insights linked to higher flu vaccination rates and fewer flu-related acute care events among Medicare Advantage patients with chronic disease.
Key results: CA PCPs had 1.39x vaccination odds; provider completion of the flu insight raised odds to 1.89x. CA relationships correlated with 17% lower COPD acute-event incidence and 11% lower CHF incidence, plus 22% fewer COPD encounters and 18% fewer CHF encounters.
Clover Health (Nasdaq: CLOV) is live on Kno2 and participating in CMS-aligned interoperability initiatives, enabling real-time, patient-directed responses for clinical and claims data using FHIR (USCDI v3) standards.
Participation is powered by Counterpart Health infrastructure and Kno2 routing; live demonstrations will run March 10–12, 2026 at HIMSS 2026.
Clover Health (Nasdaq: CLOV) announced it is the first payer live on a CMS Aligned Network and TEFCA for patient-directed requests, enabling real-time responses to clinical and claims data in standardized FHIR (USCDI v3) formats. Counterpart Health powers the underlying infrastructure and Kno2 routes secure requests across the network.
The milestone enables authenticated Medicare members to request and receive structured clinical and claims data in real time, and Clover, Kno2, and Counterpart will demonstrate an end-to-end response at HIMSS 2026, March 10–12 at Kno2 booth #12720.